Insider filing · BIOA

Vijay Satyanand Pande bought $16.2M of BioAge Labs (BIOA)

Executed Sep 27 2024, disclosed Sep 27 2024, the same day.

Over the 21 trading sessions from the disclosed entry session (Sep 27 2024), the stock returned +24.7% (delay-adjusted); from the execution session (Sep 27 2024), +24.7%. Derived: entry at the session's open, exit at the close 20 sessions later.

VP Vijay Satyanand Pande Director profile →

Vijay Satyanand Pande (Director) filed 2 Form 4 reports in the past 24 months (2 purchases, 0 sales), most often in BioAge Labs, Inc. (BIOA). Across 2 priced purchase filings, the average 21-session return was +22.4% from execution and +22.7% from disclosure (delay-adjusted; derived). The largest single filing was $16.2M of BIOA (900,000 sh × $18.00, as filed), executed Sep 27 2024.

BIOA BioAge Labs, Inc. BIOA · Healthcare · 13 filings in 24 months ticker →

Healthcare · BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→